This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novo Nordisk expects sales and profits to shrink substantially in 2026 as competition from Eli Lilly and pricing pressure from the U.S. government chip away at its multibillion-dollar obesity drug business. The news delivered midday Tuesday shook investors and Wall Street analysts, sending Novo shares tumbling by double digits on stock exchanges in the U.S. a ...

Novo Nordisk said Tuesday that fourth-quarter sales of Wegovy rose 17% on year. - Tom Little/Reuters Shares in Wegovy maker Novo Nordisk slid in early European trading Wednesday after guidance for the year ahead disappointed investors. In Copenhagen, the stock tumbled 19% at the opening bell after shares closed 15% lower in New York following Tuesday’s release of the company’s 2026 forecast. Most Read from The Wall Street Journal The Danish drugmaker said Tuesday that adjusted sales and operating profi ...

Core Insights - Novo Nordisk's stock experienced an 18% drop following a surprise pre-release of its 2026 forecast, indicating a decline in sales and operating profit between 5% and 13%, which was worse than analysts' expectations [1][4] - CEO Mike Doustdar acknowledged the challenges posed by significantly lower U.S. pricing for its weight loss drug Wegovy, suggesting that a recovery may take time [2][6] - The company faces competition from cheaper alternatives and rivals like Eli Lilly, impacting its pricing strategy in the U.S. market [6][7] Financial Guidance - The guidance for 2026 indicates a decline in both sales and operating profit, which has led to significant market reactions, reminiscent of previous guidance cuts that resulted in sharp stock declines [4][8] - Analysts from Barclays noted that the current guidance might be overly conservative, similar to past instances where initial forecasts were not met [4] Market Dynamics - The launch of the Wegovy pill in the U.S. exceeded expectations, with 170,000 people using it within four weeks, showcasing strong initial demand despite pricing pressures [7] - The market is questioning whether the recovery will follow a "Nike swoosh" or a "U-shaped" pattern, indicating uncertainty about the timing and nature of the recovery [8]

Core Viewpoint - PPL Corporation and PPL Electric Utilities reaffirm their commitment to transparency, affordability, and collaboration in response to rising energy costs and the recent Budget Address by Governor Shapiro [1][2]. Ratemaking Transparency - PPL Electric supports enhanced transparency in the regulatory process, including full rate reviews and regular audits, to build public confidence in utility regulation [3]. Reforming Retail Markets - The company advocates for measures to protect customers from deceptive retail energy practices, highlighting that retail shopping abuses cost residential customers over $60 million in 2025 [4]. Eliminating Unnecessary Fees - PPL Electric aims to revise or eliminate "junk" fees that do not add value, which could lower customer bills, and is committed to supporting vulnerable customers [5]. Customer Protections - The company continues to uphold customer protections even without current laws and supports the reinstatement of Chapter 14, which expired in December 2024 [6]. Cost Management and Reliability - Over the past decade, PPL Electric has managed operating and maintenance expenses nearly 25% below inflation while investing in grid reliability, avoiding distribution base rate increases since 2015 [7]. Economic Development - PPL Electric's infrastructure investments support economic development projects, such as the Eli Lilly project, contributing to job creation and stability in Pennsylvania [8]. Energy Supply Prices - Rising energy supply costs are a significant concern, with supply prices for PPL Electric customers increasing by over 200% in the last five years, accounting for 47% of a typical residential bill [9][10]. Generation Capacity - The company supports building new generation capacity as a key strategy to lower energy bills and has engaged in a joint venture to support data center load growth [11]. Stakeholder Collaboration - PPL Electric is dedicated to collaborating with policymakers and stakeholders to develop effective solutions for energy cost challenges while ensuring safety and reliability [12]. Company Overview - PPL Corporation is a leading U.S. energy company serving over 3.6 million customers, focusing on building resilient power grids and advancing sustainable energy solutions [13]. PPL Electric Utilities Overview - PPL Electric Utilities provides reliable electricity to about 1.5 million customers in Pennsylvania and is recognized for its reliability and customer satisfaction [14].

>> LIVE FROM WASHINGTON, D. C. , THIS IS BALANCE OF POWER WITH JOE MATHIEU.JOE: THE BILL PASSED THE TEST VOTE. WELCOME TO THE TUESDAY EDITION AS LEGISLATION TO REOPEN THE GOVERNMENT CLEARS A REGULATORY HURDLE, SETTING UP A LIKELY FULL PASSAGE OF THIS BILL TO REOPEN GOVERNMENT BEFORE THE HOUR IS OUT. WE WILL FIND OUT TOGETHER WITH AN UPDATE AHEAD FROM BLOOMBERG'S WASHINGTON CORRESPONDENT, TYLER KENDALL.SHE IS AT THE WHITE HOUSE WHICH PLAYED A PROMINENT ROLE IN GETTING REPUBLICANS TO A YES. INSIGHTS AHEAD FRO ...

Novo Nordisk's U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit.The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning. Novo's American depositary shares fell 11% as of 12:05 pm ET. The results were published after the closing bell in Copenhagen, where the company has its primary listing.Its forecast comes as the Danish drugmaker is fighting to regain ...

Pfizer Stock Dives On Modest Guidance, Obesity Update; Can It Catch Eli Lilly? | Investor's Business DailyBREAKING: [Stocks Edge Higher As Teradyne, Palantir Surge]---Pfizer (PFE) stock toppled Tuesday after the S&P health giant reaffirmed its modest outlook for 2026 despite easily beating Wall Street's fourth- quarter expectations. The company also provided an update on its obesity treatment, MET-097i, saying patients who tested a weekly dose for 12 weeks followed by monthly doses up to 28 weeks lost, on a ...

Investment Rating - The report indicates a positive outlook for China's biopharma sector, highlighting its transition into a more mature phase characterized by self-sufficiency and innovation [3]. Core Insights - China's biopharma sector is increasingly self-sufficient, supported by domestic funding and innovation, leading to a competitive edge in early-stage asset generation [3]. - The outlicensing market in China is expected to remain active, expanding into new therapeutic areas beyond oncology [3]. - Despite a pullback from non-domestic venture capital, domestic funding is reinforcing a self-reliant ecosystem in China's biopharma landscape [3]. - The report emphasizes that US restrictions may disrupt US biopharma innovation more than they will slow China's progress [3]. Summary by Sections Internal Dynamics of China's Biopharma Landscape - China's biopharma ecosystem is evolving from a generics powerhouse to a leader in next-generation therapeutics, supported by efficient clinical-trial infrastructure [5]. - The number of Investigational New Drug (IND) applications for innovative drugs increased significantly from 688 in 2019 to 2,298 in 2023 [5]. - China has adopted international standards for clinical trials, allowing companies to save 12 to 18 months in trial initiation compared to the US [5]. Global Engagement with China: Cross-Border Trends - China's licensing activity has increased, with a focus on complex biologics rather than legacy modalities [48]. - In 2025, antibodies and antibody-drug conjugates (ADCs) were the most licensed modalities, with significant deal values indicating their strategic importance [50][52]. - The report notes a trend of US and EU biopharma companies establishing centers of excellence in China to leverage local innovation [56][59]. Looking Ahead to 2026: Risks, Opportunities, and Geopolitical Trajectories - The BIOSECURE Act may introduce friction in cross-border collaborations but is primarily focused on downstream execution rather than early-stage asset generation [74]. - Despite potential disruptions, the demand for early-stage assets is expected to remain strong, particularly in precision oncology and cell and gene therapy [71][73]. - The report suggests that China's early-stage asset advantage is likely to persist due to rising US costs and funding constraints [74].

ROMAINE: A BOUNCEBACK AND U.S. MANUFACTURING LEADS TO REBOUND IN U.S. EQUITIES. HERE AT BLOOMBERG HEADQUARTERS IN NEW YORK, I'M ROMAINE BOSTICK. KATIE: WE'RE KICKING YOU OFF TO THE CLOSING BELL HERE IN THE U.S., THE S&P 500 HEADING FOR RECORD HIGH.HIGHER BY ABOUT .5% RIGHT NOW. WE HAD U.S. ISM MANUFACTURING COME IN STRONG AS MORNING, YOU SEE THAT IN THE NASDAQ 100, GIVING A LIFT TO YIELDS. FOR KNOCKING ON THE DOOR OF 4.30%, THEN YOU LOOK AT THE DOLLAR, CONTINUING TO RALLY.BLOOMBERG DOLLAR SPOT INDEX HIGHER ...

Group 1 - Novo Nordisk A/S (NYSE:NVO) is involved in manufacturing pharmaceuticals for chronic conditions such as diabetes, obesity, and rare blood or endocrine disorders, along with some medical devices [3] - The stock is currently viewed as a hold by analysts, with positive sentiments expressed after meetings with the company's CEO, indicating a potential turnaround for the company [3] - The company is noted to have a competitive advantage with its upcoming pill form of medication, which is seen as a significant development in its product offerings [3] Group 2 - Comparatively, certain AI stocks are considered to offer greater upside potential and less downside risk than Novo Nordisk, suggesting a shift in investment focus for some investors [4]